Can you provide a concise hypertension management cheat sheet for a patient with chronic kidney disease, type 2 diabetes mellitus, and heart failure with reduced ejection fraction?

Hypertension Management Cheat Sheet: CKD + Type 2 Diabetes + HFrEF

Blood Pressure Target

Target BP <130/80 mmHg in this patient population 1, 2. This stricter target is appropriate given the high cardiovascular risk from the combination of CKD, diabetes, and HFrEF 3.

---

First-Line Medication Algorithm

Step 1: Foundation Therapy (Start ALL of these)

ACE inhibitor or ARB (mandatory unless contraindicated)

• Essential for CKD with diabetes and HFrEF
• Monitor creatinine (acceptable rise up to 30%) and potassium within 1-2 weeks
• Do NOT stop for mild hyperkalemia—use potassium management strategies instead 2

Beta-blocker (mandatory for HFrEF)

• Use bisoprolol, carvedilol, or metoprolol succinate
• Bisoprolol may accumulate in severe renal impairment but still titrate to target dose (10 mg daily) or maximum tolerated 4
• Safe and effective even without overt hypertension 5

SGLT2 inhibitor (mandatory for all three conditions)

• Use dapagliflozin (eGFR ≥25 mL/min/1.73 m²) or empagliflozin (eGFR ≥20 mL/min/1.73 m²)
• Provides cardiovascular, renal, and HF benefits beyond BP lowering 3, 4
• Expect modest BP reduction (~2-3 mmHg systolic) 6

Mineralocorticoid receptor antagonist (MRA) (mandatory if eGFR ≥30)

• Use finerenone preferentially for combined cardiorenal protection in diabetes with CKD 7
  • Dose: 10 mg daily if eGFR 25-60; 20 mg daily if eGFR >60
  • Uptitrate to 20 mg after 1 month if potassium ≤4.8 mmol/L
  • Reduces cardiovascular events (HR 0.86), HF hospitalizations (HR 0.71), and kidney disease progression (HR 0.77) 7
• Alternative: Spironolactone 12.5-25 mg daily (start low: 6.25-12.5 mg or every other day) 4
• Monitor potassium closely—expect 10.8% incidence of hyperkalemia but only 1.2% discontinuation rate 7

---

Step 2: Additional Agents to Reach BP Target

If BP remains >130/80 mmHg on foundation therapy:

Calcium channel blocker (CCB)

• Amlodipine or other dihydropyridine preferred
• Safe in CKD and complements RAS inhibition 3

Thiazide-like diuretic

• Chlorthalidone or indapamide preferred over hydrochlorothiazide
• More effective in CKD than traditional thiazides 1, 3

Loop diuretic

• If volume overload present or eGFR <30 mL/min/1.73 m²
• Essential for HFrEF symptom management

---

Step 3: Resistant Hypertension (BP uncontrolled on 3+ drugs)

If already on ACE/ARB + beta-blocker + CCB/diuretic:

1. Optimize MRA dosing (if not already maximized) 1
2. Add doxazosin (alpha-blocker) 1
3. Consider bisoprolol if different beta-blocker used 1
4. Renal denervation may be considered at high-volume centers (achieves -8.5 mmHg reduction) 1, 6

---

Critical Hyperkalemia Management Strategies

Do NOT automatically stop ACE/ARB or MRA for mild hyperkalemia 2. Instead:

• Dietary potassium restriction (<2-3 g/day)
• Oral potassium binders (patiromer, sodium zirconium cyclosilicate)
• Reduce MRA dose before discontinuing
• Ensure adequate diuresis (loop diuretic optimization)
• Only discontinue if potassium persistently >6.0 mmol/L despite interventions

---

Lifestyle Modifications (Non-Negotiable)

• Sodium restriction <2 g/day (strongly recommended) 3
• Moderate-intensity exercise ≥30 minutes, 5-7 days/week 3
• DASH diet principles 1

---

Monitoring Schedule

First 1-2 weeks after initiation/titration:

• Creatinine and potassium
• Accept creatinine rise up to 30% from baseline
• BP measurement (home monitoring preferred)

Monthly during titration phase:

• Electrolytes, creatinine
• BP assessment
• HF symptoms

Every 3-6 months once stable:

• Comprehensive metabolic panel
• Urine albumin-to-creatinine ratio
• NT-proBNP (optional for risk stratification) 6

---

Common Pitfalls to Avoid

1. Clinical inertia: Failing to uptitrate medications to target doses due to fear of side effects 8
2. Premature discontinuation: Stopping ACE/ARB or MRA for mild hyperkalemia (K+ 5.5-6.0) without trying management strategies first
3. Ignoring SGLT2i: Not prescribing despite clear mortality benefit across all three conditions
4. Underdosing MRA: Starting spironolactone 25 mg in CKD—start at 6.25-12.5 mg instead 4
5. Wrong diuretic choice: Using hydrochlorothiazide instead of thiazide-like agents in CKD
6. Sacubitril/valsartan in severe CKD: Not recommended if eGFR <30 mL/min/1.73 m² 4

---

Medication Contraindications in This Population

• Avoid sacubitril/valsartan if eGFR <30 4
• Avoid MRA if eGFR <30 or baseline K+ >5.0 mmol/L (relative contraindication—use with extreme caution and close monitoring)
• Avoid NSAIDs (worsen CKD, HF, and BP control)
• Avoid non-dihydropyridine CCBs (diltiazem/verapamil) in HFrEF due to negative inotropic effects